Current News

Study Results Show Significant Overall Cost Savings with St. Jude Medical Quadripolar System

St. Jude Medical has recently announced that data presented during Heart Rhythm 2014, the Heart Rhythm Society’s Annual Scientific Sessions, found that the use of quadripolar leads reduced the number of hospitalisations by 53 percent when compared to the non-quadripolar group. This hospitalisation rate reduction translated into a statistically significant 62 percent reduction in overall costs for both health care systems and patients.

The Hospitalisation Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-centre prospective Italian registry presentation includes data that demonstrated hospitalisation rates for the quadripolar group were lower than the non-quadripolar group and patients with the St. Jude Medical Quartet™ Quadripolar LV lead and had a 98 percent probability of having lower costs than patients with non-quadripolar leads. The study showed that use of the quadripolar left ventricular (LV) lead was associated with significantly reduced hospitalisations specific to the two types of hospitalisations studied: heart failure and LV lead surgical revision.

“These data are compelling evidence as they show a significant cost saving for the health care system and patients utilising the St. Jude Medical quadripolar pacing system,” said Dr. Giovanni Forleo, electrophysiologist at the University Hospital of Tor Vergata, Rome, Italy. “This study showed a strong cost benefit, further demonstrating why quadripolar technology is becoming the standard-of-care for patients requiring CRT therapy.”

The prospective, single centre, observational registry was a first-time evaluation of hospitalisation rates and cost reduction following cardiac resynchronisation therapy (CRT) with quadripolar versus non-quadripolar LV leads. Over three years, 198 patients implanted with either a St. Jude Medical Quartet Quadripolar LV lead or a non-quadripolar LV lead, were enrolled in the study. The goal of the study was to compare the hospitalisation rate related to heart failure and LV lead surgical revisions between the Quartet quadripolar lead and a traditional bipolar lead for cardiac resynchronisation therapy defibrillators (CRT-D).

“This study provides additional evidence that the quadripolar system improves patient outcomes and reduces health care costs,” said Dr. Mark D. Carlson, chief medical officer and vice president of global clinical affairs for St. Jude Medical. “This study is another example of St. Jude Medical’s commitment to investing in disruptive technologies that transform the treatment of expensive epidemic diseases.”

If you would like more information about the study or about St. Jude's quadripolar system, please contact your local PEI hospital representative or call PEI at +353 1 419 6900.


February 2020
27 28 29 30 31 1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 1
2 3 4 5 6 7 8